Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan

20-F - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

- The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD ("SKATBT-A3"), which measures the effectiveness of the treatment on the patient's overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. - The first efficacy trial using personalized TCM formulae have shown a mean percentage improvement of 30% in ADHD symptoms and a mean percentage improvement of 37% in ASD symptoms, based on the scoring systems under the Vanderbilt ADHD Diagnostic Parent Rating Scale ("VADRS") and the Autism Treatment Evaluation Checklist ("ATEC"), respectively, after 3 months of treatment. - The ongoin

Regencell Bioscience Holdings Limited (NASDAQ:RGC): Results of EARTH efficacy trial   EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patients) 90.2 83.8 87.5 Testing negative in 6 days (% of patients) 23.5 43.5 29.7 Recovery period for patients who took RGC-COV19TM within 3 days of sy

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman and CEO, made purchases of ordinary shares in Regencell ("Ordinary Shares") totaling $5.03 million. Based on his Schedule 13D filings with the U.S. Securities and Exchange Commission (the "SEC") between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of his personal funds to

36 out of 37 COVID-19 patients treated in the trial, representing approximately 97.3% of the patients, reported they had all symptoms eliminated within the 6-day treatment period save for loss or reduced sense of taste and smell ("Sensory Dysfunction") and occasional cough. The highest number of different symptoms reported for any one individual was 14. 15 out of the 36 patients experienced Sensory Dysfunction prior to receiving treatment. Among those 15 patients, 5 recovered their sensory functions while the remaining 10 showed improvements at the end of the 6-day treatment period. 31 out of 37 COVID-19 patients, representing approximately 83.8% of patients, reported the elimination o

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807. As per the Schedule 13D filed with the SEC on November 22, 2021, Mr. Au has used an aggregate of $1,125,807 of his personal funds to purchase Ordinary Shares made through the Reporting Persons' Rule 10b-18 Plan. According to the 10b-18 Plan, fo

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective December 1, 2021). MSCI Inc., a leading provider of research-based indexes and analytics, announced Regencell's addition on November 11, 2021, following results of their semi-annual index review. Launched on December 1, 2010, the

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), today announced that Regencell Bioscience Limited ("Regencell HK"), the Company's wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises Limited ("Honor Epic"). The joint venture ("JV") is expected to offer COVID-19 ("COVID") related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since March 2020, Mr. Sik-Kee A

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD"), today announced that the underwriter of its initial public offering (the "Offering") had exercised its option to purchase 325,000 additional ordinary shares at the public offering price of US$9.50 per share to cover over-allotments. Gross proceeds from the Offering, including proceeds from the exercise of the over-

Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and Chief Executive Officer of the Company. Dear Shareholders: As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond. For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specificall

Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company

Shares of Enphase Energy, Inc. (NASDAQ:ENPH) rose sharply in today's pre-market trading after the company reported second-quarter financial results. Enphase Energy reported second-quarter revenue of $303.46 million, missing the consensus estimate of $309.67 million, according to Benzinga Pro. The company reported adjusted earnings of 43 cents per share, missing analyst estimates of 48 cents per share. Enphase Energy shares gained 6.2% to $110.10 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 146.2% to $3.20 in pre-market trading after falling over 22% on Tuesday. NuZee, Inc.  (NASDAQ:NUZ

Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant

Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million. NKGen Biotech (NASDAQ:NKGN) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million. NeuroMetrix (NASDAQ:NURO) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 17.24% to $0.05. The company's market cap stan

Gainers Avalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 83.33% to $1.43. The company's market cap stands at $10.4 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock moved upwards by 81.6% to $1.56. The company's market cap stands at $6.6 million. Xilio Therapeutics (NASDAQ:XLO) shares moved upwards by 67.44% to $1.07. The company's market cap stands at $29.4 million. Mesoblast (NASDAQ:MESO) shares increased by 44.12% to $5.03. The company's market cap stands at $510.4 million. Regencell Bioscience (NASDAQ:RGC)

Gainers IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The market value of their outstanding shares is at $2.8 million. Virios Therapeutics (NASDAQ:VIRI) shares increased by 37.98% to $0.46. The company's market cap stands at $8.8 million. Regencell Bioscience (NASDAQ:RGC) stock increased by 36.71% to $5.25. The company's market cap stands at $68.3 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 35.03% to $0.35. The market value of their outstanding shares is at $9.6 million. Outlook Therapeutics (NASDAQ:OTLK) shares rose 27.13% to $8.95. The market value of their outstanding shares is at $193.1 million. Biolase (NASDAQ:BIOL) shar

Gainers Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% to $0.76. The market value of their outstanding shares is at $6.4 million. Aptorum Gr (NASDAQ:APM) stock rose 11.75% to $4.84. The company's market cap stands at $25.0 million. Galecto (NASDAQ:GLTO) shares moved upwards by 10.49% to $0.83. The company's market cap stands at $22.5 million. Mira Pharmaceuticals (NASDAQ:MIRA) stock moved upwards by 9.99% to $1.21. The market value of their outstanding shares is at $17.8 million. Cyclo Therapeutics (NASDAQ:CYTH) shares increased

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 76.41% to $1.87. The company's market cap stands at $4.5 million. bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 28.1% to $1.96. The company's market cap stands at $21.8 million. Graphite Bio (NASDAQ:GRPH) stock moved upwards by 25.47% to $3.94. The market value of their outstanding shares is at $229.4 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 24.8% to $0.78. The company's market cap stands at $13.0 million. Mesoblast (NASDAQ:MESO) stock rose 22.79% to $2.

Gainers Aptorum Gr (NASDAQ:APM) stock moved upwards by 780.6% to $12.77 during Wednesday's regular session. The company's market cap stands at $66.1 million. NKGen Biotech (NASDAQ:NKGN) stock rose 302.55% to $3.47. The company's market cap stands at $75.9 million. Trxade Health (NASDAQ:MEDS) shares increased by 88.71% to $15.72. The company's market cap stands at $18.9 million. Regencell Bioscience (NASDAQ:RGC) stock moved upwards by 80.06% to $10.39. The market value of their outstanding shares is at $135.2 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 38.94% to $0.48. The company's market cap stands at $3.5 million. Vincerx Pharma (NASDAQ:VINC) shares rose 37.61% t

Gainers Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. Regencell Bioscience (NASDAQ:RGC) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million. Genenta Science (NASDAQ:GNTA) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million. T2 Biosystems (NASDAQ:TTOO) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million. Sangamo Therapeutics (NASDAQ:SGMO) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million. Organovo Holdings (NASDAQ:ONVO) shares m

SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

SC 13G - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)